Somatrem

Somatrem Overview

Somatrem is an early-generation recombinant human growth hormone (rhGH) analogue produced using recombinant DNA technology. Chemically, it belongs to the class of amino acids, peptides, and proteins within the carboxylic acids and derivatives subclass. Structurally, Somatrem is a 192-amino acid single-chain polypeptide containing an extra N-terminal methionine residue appended to the natural 191-amino acid sequence of native human growth hormone (somatropin).

In clinical endocrinology and pediatric growth disorders, Somatrem was developed as a systemic hormonal preparation for the long-term treatment of growth failure and growth hormone insufficiency. Formulated as a lyophilized powder for reconstitution (historically marketed by Genentech and Hoffmann-La Roche under the trade name Protropin), it was indicated for pediatric patients presenting with growth hormone deficiency (GHD), idiopathic short stature (ISS), Turner syndrome (TS), or chronic kidney disease (CKD) up to the time of renal transplantation. It was also indicated for adults with childhood-onset or adult-onset growth hormone deficiency.

What Is Somatrem and How Does It Work?

Somatrem is a protein-based therapeutic hormone that functions as an agonist at the human growth hormone (GH) receptor and downstream signaling cascades.

Its primary physiological, metabolic, and cell-signaling mechanisms include:

• Growth Hormone Receptor Binding: Somatrem binds to dimeric cell-membrane growth hormone receptors on target tissues, inducing receptor dimerization, intracellular JAK2 tyrosine kinase activation, and downstream STAT-mediated gene transcription.
• IGF-1 Secretion: Binding directly stimulates the liver and local tissues (including epiphyseal cartilage) to synthesize and secrete Insulin-like Growth Factor 1 (IGF-1). Serum IGF-1 levels, which are low in growth-deficient patients, increase substantially during treatment.
• Linear Skeletal Growth: Circulating and local IGF-1 acts on the epiphyseal plates at the ends of growing long bones, stimulating chondrocyte proliferation, cartilage matrix deposition, collagen synthesis, and new bone formation. This produces linear growth until epiphyseal fusion occurs at the end of puberty.
• Protein Synthesis & Muscle Hypertrophy: Somatrem stimulates cellular amino acid uptake and protein synthesis while inhibiting protein catabolism, as evidenced by nitrogen retention, decreased urinary nitrogen excretion, and reduced blood urea nitrogen (BUN) levels. It increases both the number and size of skeletal muscle cells.

Is Somatrem FDA Approved?

Yes, Somatrem was approved by the US FDA. It received its official approval on October 18, 1985, under the trade name Protropin (developed by Genentech) as the first recombinant human growth hormone analogue approved in the United States for treating pediatric growth hormone deficiency. However, because its extra N-terminal methionine residue caused a higher incidence of neutralizing anti-GH antibody formation compared to authentic 191-amino acid somatropin, commercial distribution was voluntarily phased out, and the product was officially withdrawn from the US market on June 30, 2004.z

What Is Somatrem Used For?

• Long-term treatment of pediatric patients with growth failure due to inadequate secretion of normal endogenous growth hormone (growth hormone deficiency).
• Treatment of pediatric growth failure associated with idiopathic short stature (ISS).
• Treatment of growth failure in pediatric patients with Turner syndrome (TS).
• Treatment of growth failure in pediatric patients with chronic kidney disease (CKD) prior to renal transplantation.

Before Taking Somatrem: Contraindications & Precautions

Strictly contraindicated in patients with closed epiphyses who have completed skeletal maturation, active neoplasia, ongoing intracranial tumor progression, severe acute illness due to major surgery or trauma, or severe diabetic retinopathy. Do not use it if you have a documented hypersensitivity to Somatrem, benzyl alcohol, or product excipients. Somatrem was voluntarily phased out and officially withdrawn from the U.S. market in 2004 due to high neutralizing anti-GH antibody rates caused by its extra N-terminal methionine residue; modern non-methionyl somatropin preparations are used instead. Use during pregnancy and lactation should occur only under clear medical necessity.

Who Should Not Take Somatrem?

• Patients with closed epiphyses who have completed skeletal maturation.
• Individuals with active neoplasia or evidence of ongoing intracranial tumor progression; anti-tumor therapy must be completed prior to initiating treatment.
• Patients with severe acute illness caused by open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure.
• Individuals with severe proliferative or non-proliferative diabetic retinopathy.

Somatrem, Pregnancy & Fertility

Systemic drug exposure occurs following parenteral administration. Animal reproduction studies with recombinant growth hormones have not demonstrated teratogenicity. However, adequate and well-controlled clinical trials in pregnant women are lacking. Somatrem should be administered during pregnancy only if clearly needed. It is unknown whether Somatrem is excreted in human breast milk; caution should be exercised when administered to a nursing mother.

Tell Your Doctor Before Taking Somatrem

Inform your endocrinologist or physician if you have a history of diabetes mellitus, scoliosis, intracranial lesions, hypothyroidism, or chronic kidney disease. Disclose all concurrent prescription medications, especially glucocorticoids, insulin, or oral hypoglycemics.

Somatrem Dosage & Administration

Somatrem (Protropin) is a discontinued, withdrawn medication, making clinical dosing guidelines obsolete. Formulated as a lyophilized powder for reconstitution with bacteriostatic water for subcutaneous or intramuscular injection. Historically, pediatric GHD dosing was up to 0.30 mg/kg weekly in divided doses, while Turner syndrome dosing was up to 0.375 mg/kg weekly. Reconstituted vials were swirled gently without shaking and injected into rotated sites (thighs, abdomen, buttocks) to prevent localized lipodystrophy. It is no longer manufactured or available for legal medical administration.

Standard Somatrem Dosing

• Pediatric Growth Hormone Deficiency: The historical recommended dosage was up to 0.30 mg/kg of body weight per week, divided into daily or 3-times-weekly intramuscular or subcutaneous injections.
• Turner Syndrome: Dosages up to 0.375 mg/kg of body weight per week were utilized, divided into daily subcutaneous injections.
• Adult Growth Hormone Deficiency: Initial doses typically started at 0.005 mg/kg daily, titrated up to a maximum of 0.0125 mg/kg daily based on serum IGF-1 levels and tolerance.

How Somatrem Was Administered

• Administered via the subcutaneous or intramuscular route.
• Reconstitute lyophilized powder with provided sterile diluent (bacteriostatic water for injection).
• Gently swirl the vial during reconstitution; do not shake vigorously to avoid protein denaturation.

Somatrem Clinical Efficacy & Research

Pivotal clinical trials conducted in the 1980s and 1990s confirmed that Somatrem effectively stimulated linear growth in children with growth hormone deficiency, increasing annual growth velocity from pre-treatment levels of <4 cm/year to over 8 to 10 cm/year during the first year of therapy. Clinical studies confirmed significant increases in serum IGF-1 concentrations, lean body mass, and bone mineral density. However, long-term immunogenicity studies revealed that approximately 30% of patients developed circulating antibodies to Somatrem due to its extra methionine residue, although growth attenuation occurred in only a small subset. This finding accelerated the transition to recombinant 191-amino acid somatropin.

Somatrem Side Effects & Safety Profile

Common reactions included injection site pain, swelling, erythema, lipodystrophy, peripheral edema, joint stiffness, arthralgias, myalgias, and transient elevations in inorganic phosphorus and alkaline phosphatase. Serious adverse risks included high rates of neutralizing anti-GH antibody formation, intracranial hypertension (pseudotumor cerebri with papilledema and severe headache), slipped capital femoral epiphysis (presenting as limping or hip/knee pain), impaired glucose tolerance, and progression of pre-existing scoliosis. Holds no FDA Black Box Warning.

Common Somatrem Side Effects

• Localized injection site pain, swelling, redness, or lipodystrophy.
• Mild fluid retention, presenting as peripheral edema, stiffness, or joint pain (arthralgias).
• Transient headache, muscle pain (myalgia), and mild weakness.
• Increased serum inorganic phosphorus, alkaline phosphatase, and urinary hydroxyproline.

Serious Somatrem Adverse Events

• Development of Neutralizing Anti-GH Antibodies: Higher incidence compared to somatropin, potentially blunting long-term growth response.
• Intracranial Hypertension (Pseudotumor Cerebri): Papilledema, visual changes, severe headache, nausea, and vomiting.
• Slipped Capital Femoral Epiphysis: Limping, hip pain, or knee pain in pediatric patients experiencing rapid linear growth.
• Impaired Glucose Tolerance & Hyperglycemia: Decreased insulin sensitivity leading to elevated fasting insulin and blood glucose levels.

Managing Somatrem Side Effects

Monitor pediatric patients for limping or hip pain during rapid growth phases. If severe headache or visual disturbances occur, perform funduscopic examination to rule out intracranial hypertension. If hyperglycemia occurs, adjust oral anti-diabetic agents or insulin.

Somatrem Drug Interactions & What to Avoid

Excessive glucocorticoid administration (e.g., prednisone, hydrocortisone) antagonizes the growth-promoting effects of Somatrem, requiring careful dose titration of hormone replacement. Somatrem decreases insulin sensitivity, requiring dosage adjustments of insulin or oral antidiabetic agents in diabetic patients. Growth hormone may alter hepatic CYP450 enzyme activity, impacting the clearance of co-administered drugs.

Somatrem Drug-Drug Interactions

• Glucocorticoids (e.g., Prednisone, Hydrocortisone): Excessive glucocorticoid administration antagonizes the growth-promoting effects of Somatrem. Patients on hydrocortisone replacement must have their doses carefully titrated.
• Insulin and Oral Hypoglycemics: Somatrem decreases insulin sensitivity, requiring adjustments in anti-diabetic drug dosages in diabetic patients.
• Cytochrome P450 Metformin/Substrates: Growth hormone may alter hepatic CYP450 clearance of co-administered drugs; monitor therapeutic drug levels.

Somatrem, Food & Alcohol

Maintain a well-balanced diet rich in protein, calcium, and essential nutrients to support bone and tissue synthesis during active growth therapy.

Somatrem: Missed Dose, Overdose & Storage

Dosing schedules are obsolete due to market withdrawal. Acute overdose causes initial hypoglycemia followed by hyperglycemia; chronic overuse causes acromegalic features in adults or gigantism in pediatric patients prior to epiphyseal fusion, requiring immediate supportive medical evaluation and glucose monitoring. Un-reconstituted vials were stored refrigerated (2°C–8°C) protected from light and freezing; reconstituted solutions were used within 14 days.

Missed Dose of Somatrem

Administer the missed dose as soon as remembered on that day. If it is almost time for the next scheduled dose, skip the missed dose and resume your regular injection schedule. Do not double up doses.

Somatrem Overdose & Emergency

Acute overdose causes initial hypoglycemia followed by hyperglycemia. Chronic overuse leads to acromegalic features (in adults) or gigantism (in pediatric patients before epiphyseal fusion), along with fluid retention and organomegaly. In cases of acute accidental toxicity, seek immediate medical attention for glucose monitoring and supportive care.

How to Store Somatrem

Store un-reconstituted vials under refrigeration between 2°C and 8°C (36°F to 46°F). Protect from direct light and freezing. Reconstituted solutions prepared with bacteriostatic water should be refrigerated and used within 14 days. Keep strictly out of reach of children.

Somatrem Patient Management & Monitoring

Historical monitoring required baseline provocative growth hormone stimulation testing, baseline serum IGF-1, IGFBP-3, fasting glucose, thyroid function panels, a funduscopic eye examination, and hand/wrist bone age X-rays. During treatment, linear height velocity was evaluated every 3 to 6 months, and bone age was assessed annually. Routinely monitor fasting glucose, thyroid function, serum IGF-1, anti-GH antibody titers, and evaluate immediately for limping, hip pain, or severe headaches.

Tests Before Starting Somatrem

• Baseline provocative growth hormone stimulation testing to confirm GHD diagnosis.
• Baseline serum IGF-1, IGFBP-3, fasting glucose, thyroid function panel (TSH, free T4), and lipid profile.
• Funduscopic eye examination and baseline hand/wrist X-ray to assess bone age.

Monitoring During Somatrem Treatment

Monitor linear height velocity every 3 to 6 months. Evaluate hand/wrist bone age annually. Periodically assess thyroid function, fasting glucose, serum IGF-1, and anti-GH antibody titers.

Somatrem Do’s and Don’ts

• Do rotate subcutaneous injection sites daily.
• Do inspect reconstituted liquid; do not inject if cloudy or containing particulate matter.
• Do report limping, hip pain, or severe headaches to your doctor immediately.
• Do not shake the reconstituted vial vigorously.
• Do not discontinue therapy without consulting your pediatric endocrinologist.

Frequently Asked Questions

References

• DrugBank Database – Somatrem Clinical and Pharmacological Profile (DB09098)
• Classyfire Database – Amino Acids, Peptides, and Analogues Chemical Taxonomy Profile

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex cardiovascular conditions, medication adjustments, or dietary changes.